FG-3019 is a human anti-CTGF IgG1 monoclonal antibody currently under clinical investigation as a potential therapeutic for treatment of idiopathic pulmonary fibrosis, liver fibrosis and pancreatic cancer (5). This evidence concerns the gene CCN2 and familial pancreatic carcinoma.